-
07.25.2024 | House Budget Committee examines budgetary effects of antimicrobial resistance and the broken antibiotic development pipeline
CARB-X Executive Director Kevin Outterson joined other industry experts at a House Budget Committe bipartisan roundtable entitled “Threats to Modern Medicine: Examining the Budgetary Effects of Antimicrobial Resistance and the Broken Antibiotic Development Pipeline.”
-
04.17.2024 | As antimicrobial resistance looms large, a nonprofit teams up with Big Pharma to intervene
PHARMAVOICE | AMR is a growing threat, but with little financial incentive to pick up the torch, government and nonprofit collaborations are keeping the R&D flames burning.
-
03.08.2024 | Professor Kevin Outterson speaks on antimicrobial resistance
TUFTS DAILY | Kevin Outterson, a professor at Boston University, bridges economics, health equity and scientific research in his discussion about how to combat antimicrobial resistance.
-
03.06.2024 | Non-profits take over from Big Pharma in new drugs trials
JUTA MEDICAL BRIEF | Effective, affordable antimicrobial drugs are desperately needed around the world, and last November, a clinical trial offered a glimmer of hope, when an oral antibiotic, called zoliflodacin, was shown to be effective against the bacterium that causes gonorrhoea.
-
03.06.2024 | CARB-X funds 100th project—a milestone for BU-based nonprofit leading antimicrobial-resistance fightback
THE BRINK | Global partnership led by BU law professor has now given $452.6 million in funding to support promising new antibiotics, vaccines, and rapid diagnostics—and is ready to support more projects.
-
03.05.2024 | With new award, CARB-X hits the 100-project mark in battling antibiotic resistance
CIDRAP | CARB-X today announced funding for its 100th project addressing antimicrobial resistance (AMR).
-
02.28.2024 | Can non-profits beat antibiotic resistance and soaring drug costs?
NATURE | Last November, a clinical trial offered a glimmer of hope in the often gloomy fight against antimicrobial resistance. An oral antibiotic, called zoliflodacin, was shown to be effective against the bacterium that causes the sexually transmitted disease gonorrhoea.
-
02.15.2024 | Could a single synthetic molecule outsmart a variety of drug-resistant bacteria?
LOS ANGELES TIMES | An estimated 2.8 million people in the U.S. contract infections each year from bacteria resistant to antibiotics, according to the U.S. Centers for Disease Control. More than 35,000 of them die.
Toggle navigation